Barnes & Noble Shares Soar After Investor Discusses Sale with Founder
07 Sep, 2018
Novo Nordisk AS (NYSE: NVO) posted better than expected results for the fiscal year. Shares were up over 8 percent after open on Thursday.The pharmaceutical company reported an 8 percent in operating profits in the first six months of the 2017...
Esperion Therapeutics Inc (NASDAQ: ESPR) announced positive top-level results for Phase 2 of trials for triplet oral therapy with bempedoic acid, ezetimibe and atorvastatin.The trials, which lasted six weeks, have yilded positive data as the LDL-C l..
On Tuesday, Valeant Pharmaceuticals Intl Inc (NYSE: VRX) announced its financial results for the second quarter. With earnings beating estimates, shares of the company increased 7.6% to $16.54 per share in morning trading on Tuesday after the announ..
On Friday, billionaire investor William Ackman announced that he will be buying a large stake in Automatic Data Processing Inc.(NASDAQ:ADP), a move that made the U.S. payroll company’s stock increase 16.5% to $120.In recent years, activi..
AstraZeneca plc (NYSE: AZN) released a bevy of news today, including Q2 results, as well as study results for two drugs. AZN price has plummeted 15%.Following the loss of exclusivity for Crestor and Seroquel XR AstraZeneca had expected losses in the..
Novartis AG (NYSE: NVS) is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The U.S. Food and Drug Administration will ask a panel of advisers to focus on the safety of ..
Shares of Cara Therapeutic Inc. (NASDAQ: CARA) fell 31 percent on Friday after the company announced disappointing results on the CR845 oral medication from a phase 2b trial.Cara is a biopharmaceutical company that focuses on developing medications ..
All rights reserved.
No portion of Financialinsiders.com may be duplicated, redistributed or manipulated in any form without our consent, violators will be prosecuted to the full extent of the law. By accessing any information beyond this page, you agree to abide by the Privacy Policy and Terms of Use (Disclaimer).